Please login to the form below

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

Baxalta and CTI complete filing for Jakafi rival in US

Baxalta and CTI complete filing for Jakafi rival in US. Myelofibrosis candidate pacritinib aiming for accelerated approval. ... Baxalta's former parent company Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m.

Latest news

Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial. Myelofibrosis candidate pacritinib moves closer to market. ... Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Baxter licenses cancer drug from CTI in $172m deal. Pacritinib is being investigated to treat blood disorder myelofibrosis. ... he added, noting that additional data on pacritinib will be presented at the American Society of Haematology (ASH) conference
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.
Gilead expands in cancer with $510m YM BioSciences deal

pacritinib, which was licensed earlier this year from Singaporean company S Bio in a $30m deal.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer: Great salary and bebefits

Scientific Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Medical Writer, e-learning/ training, London: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer: Great salary and benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Programme Executive: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...